Based on its recent analysis of the finished heparin market, Frost & Sullivan recognizes Sagent Pharmaceuticals, Inc. with the 2011 North American Frost & Sullivan Award for Product Quality Leadership. Sagent Pharmaceuticals' recently approved line of superior heparin injection preparations is available in a wide assortment of concentrations and package sizes, which are supplied in clearly labeled and color-differentiated packages to simplify use and help prevent medication errors. The availability of a variety of strengths and package sizes from a single supplier also helps to facilitate ordering, dispensing and administration.
Recently, the medical community was faced with a severe shortage of heparin due to the toxic contamination of heparin active pharmaceutical ingredients (APIs) and the resulting nationwide withdrawal of a large portion of the heparin supply. Sagent Pharmaceuticals helped alleviate this situation by locating an alternative supplier of safe ingredients to produce finished heparin preparations. These products were able to pass both the United States Pharmacopeia (USP) and the Food and Drug Administration's (FDA's) stringent new standards and eventually, the company launched its line of heparin injection products.
"Consumer confidence in the product's reliability is reflected in Sagent's rapid market uptake, leading to approximately 18.6 percent market share in just six months, and eventually, 25.4 percent for the first year on the market," says Frost & Sullivan Industry Analyst Debbie Toscano. "The true value of this product lies in the purity of the ingredients and user-friendly packaging, both of which Sagent delivers."
Sagent Pharmaceuticals' heparin injection product labeling was designed using the company's proprietary PreventIV MeasuresSM Packaging and Labeling, which is a user-centric approach to product packaging and labeling. Its unique features include easy-to-read product name, concentration and fill volume, and bold, color-differentiated labels, caps and cartons. Such detailed labeling clearly distinguishes each product and offers greater overall value for buyers, wholesalers, pharmacists, clinicians and patients.
"Since there are eleven unique total strengths of heparin sodium injection but only four different solution concentrations, the traditional labeling approach to this product makes it very easy for users to select the right concentration but the wrong total strength," notes Toscano. "Therefore, in addition to the use of a unique color for each total strength, Sagent has placed the vial fill volume information directly adjacent to the concentration information."
To further clarify the intended use of the product, Sagent has included a die cut warning strip on the vial labels and cartons, indicating that the product is not to be used as a Heparin Lock Flush, which is a common and very serious error that has led to many fatalities. Sagent Pharmaceuticals offers labeling solutions not only for the vials but the cartons as well. Unlike competitors' shrink-wrapped trays, Sagent's full-color cartons are clearly labeled on all four sides and top, as well as bar coded on two panels, enabling easy identification by purchasers and pharmacy technicians.
Heparin is frequently used in critical care as well as routine procedures such as dialysis. The required concentration and volume depends on the particular application and the dose may have to be frequently adjusted to suit the patient's body weight or individual coagulation status. Hence, a product, which is available in a variety of package sizes and concentrations under a single brand label, offers greater ease of use and eliminates the requirement to switch brands based on need.
Each year, Frost & Sullivan presents this award to a company that has developed high-quality products with innovative features and functionalities. The winner of this award has developed and launched a product that enhances customer value and finds immediate acceptance in the market. Sagent's Heparin Sodium Injection, USP with PreventIV MeasuresSM Packaging and Labeling demonstrates this leadership.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research in order to identify best practices in the industry.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.
About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.